Bone Metastasis Market Share

The Bone Metastasis Market size is expected to reach USD 17.5 Billion by 2032 at 9.4% CAGR during the forecast period 2023-2032. The spread of malignant cells from their initial place to a bone is known as bone metastasis.

Bone metastases can occur in any type of malignancy. Breast cancer and prostate cancer, on the other hand, are thought to be frequently linked to the disease. The medical issue affects the spine, pelvis, and thighs frequently. Some of the most prevalent symptoms of the condition include urinary incontinence, bowel incontinence, and hypercalcemia. During the projection period, the rising prevalence of bone metastasis is expected to be a major driver of market growth. When cancer cells break off from a primary tumor that is located elsewhere in the body, bone metastasis, often known as bone Mets, occurs. 

These cancer cells migrate to a portion of the bone through the bloodstream or the lymph system and become metastatic cancer cells. This is not the same as a primary bone tumor, which begins in the bone. Osteoclasts cause a bone breakdown in the absence of fresh bone formation, weakening the bones. Because of the benefits given by minimally invasive procedures over traditional treatment procedures, there has been a huge growth in demand for them. 

Fewer operating complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infection, reduced post-surgical care, and faster recovery are all advantages of minimally invasive procedures. There are various advanced techniques used in minimally invasive treatments to detect and treat a variety of disorders, including cancer.

Intended Audience

• Pharmaceutical Companies


• Biotechnological Institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers

Figure 1: Bone Metastasis Market Share, by Region

 

Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation

Bone Metastasis Market Segmentation

The bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the bone metastasis market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.

On the basis of diagnosis, the bone metastasis market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.

On the basis of the treatment, the bone metastasis market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.

On the basis of end-user, the bone metastasis market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers. 

Bone Metastasis Market Regional Analysis

America dominates the bone metastasis market. This can be attributed to the presence of a well-developed healthcare sector, the increasing prevalence of breast cancer, and increasing healthcare sector within the region. Moreover, the presence of key players such as Merck & Co., Inc. and Pfizer Inc. within the Americas boosts the regional market growth.

Europe is the second in the bone metastasis market owing to the availability of funds for research and a huge patient population. According to the Cancer Research U.K., approximately 55,122 new cases of invasive breast cancer were reported in 2015. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe leads the regional market due to the presence of developed economies within the region.

Asia Pacific is projected to be the fastest growing region in the bone metastasis market. The presence of developing economies such as India and China, a developing healthcare sector, and the growing prevalence of cancer within the region drive the market growth in the region. Moreover, favorable government policies and increasing penetration of key market players within the region fuel the market growth.

The Middle East and Africa holds the least share in the bone metastasis market, owing to the presence of poor economies, stringent government policies, and lack of healthcare services, especially within the African region. A majority of the market of bone metastasis in the Middle East and Africa is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure by developed economies such as Saudi Arabia, Kuwait, Dubai, and others within the region.

Recent Development

ZetaMet technology was granted a breakthrough device designation by the FDA's Centers for Devices and Radiological Health in December 2021 for use in the treatment of Bone Metastasis and osteologic treatments. The company, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc. in October 2020 to provide more upside potential in areas like Infectious Diseases and Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Key Players in the Bone Metastasis Market

The key players in the bone metastasis market are: 

• F. Hoffmann-La Roche Ltd (Switzerland)


• Bayer AG (Germany)


• Merck & Co., Inc. (U.S.)


• Pfizer Inc. (U.S.) 


• Novartis AG (Switzerland)


• Pharmalucence Inc. (England)


• Koninklijke Philips N.V. (the Netherlands)


• GENERAL ELECTRIC (U.S.)


• Siemens AG (Germany)


• TOSHIBA CORPORATION (Japan)